AC480 - CAS 714971-09-2
Not Intended for Therapeutic Use. For research use only.
Category:
Inhibitor
Product Name:
AC480
Catalog Number:
714971-09-2
Synonyms:
BMS-599626.
CAS Number:
714971-09-2
Description:
AC480, also known as BMS-599626, is an orally bioavailable inhibitor of the HER1, HER2 and HER4 tyrosine kinases (IC50 =22, 32 and 190 nM, respectively) with potential antineoplastic activity. BMS-599626 inhibits human epidermal growth factor receptors (HER) HER1, HER2 and HER4, thereby inhibiting the proliferation of tumor cells that overexpress these receptors.
COA:
Inquire
MSDS:
Inquire
Targets:
EGFR
Current Developer:
Ambit Biosciences, Inc.
Chemical Structure
CAS 714971-09-2 AC480

Related EGFR Products


CAS 873837-23-1 BMS-599626 Hydrochloride

BMS-599626 Hydrochloride
(CAS: 873837-23-1)

BMS-599626 Hydrochloride is a selective and efficacious orally bioavailable inhibitor of the HER1, HER2 and HER4 tyrosine kinases with potential antineoplastic ...

CAS 1421373-65-0 AZD-9291

AZD-9291
(CAS: 1421373-65-0)

AZD-9291 is a third-generation EGFR inhibitor, showed promise in preclinical studies and provides hope for patients with advanced lung cancers that have become ...

SKLB-1028
(CAS: 1350544-93-2)

SKLB1028 is a novel Bcr-abl tyrosine kinase inhibitor, Epidermal growth factor inhibitor and Fms-like tyrosine kinase 3 inhibitor originated by CSPC Ouyi Pharma...

CAS 714971-09-2 AC480

AC480
(CAS: 714971-09-2)

AC480, also known as BMS-599626, is an orally bioavailable inhibitor of the HER1, HER2 and HER4 tyrosine kinases (IC50 =22, 32 and 190 nM, respectively) with po...

Anlotinib
(CAS: 1058156-90-3)

Anlotibib is a multi-targetes kinase inhibitor of receptor tyrosine and could effectively resist the formation of new angiogenesis and is under Phase III trail ...

CAS 937265-83-3 ARRY-380

ARRY-380
(CAS: 937265-83-3)

ARRY-380 is a potent and selective HER2 inhibitor with IC50 of 8 nM, equipotent against truncated p95-HER2, 500-fold more selective for HER2 versus EGFR.

CAS 388082-77-7 Lapatinib Ditosylate

Lapatinib Ditosylate
(CAS: 388082-77-7)

Lapatinib is a synthetic, orally-active quinazoline with potential antineoplastic activity. Lapatinib reversibly blocks phosphorylation of the epidermal growth ...

Tarloxotinib bromide
(CAS: 1636180-98-7)

Tarloxotinib bromide, a pyridopyrimidine derivative, has been found to be a EGFR tyrosine kinase inhibitor precursor and could probably be effective in antineop...

CAS 610798-31-7 Icotinib

Icotinib
(CAS: 610798-31-7)

Icotinib Hydrochloride (BPI-2009H), or Icotinib, is a highly selective, first generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI).

CAS 289499-45-2 Canertinib dihydrochloride

Canertinib dihydrochloride
(CAS: 289499-45-2)

Canertinib dihydrochloride is the hydrochloride salt of an orally bio-available quinazoline with potential antineoplastic and radiosensitizing activities. Caner...

CAS 1110813-31-4 Dacomitinib

Dacomitinib
(CAS: 1110813-31-4)

Dacomitinib, aslo known as PF-299 and PF-00299804; or PF299804, is an orally bioavailable, highly selective, second-generation small-molecule inhibitor of the p...

CO-1686 hydrobromide
(CAS: 1446700-26-0)

CO-1686 hydrobromide is the hydrobromide salt form of CO-1686. CO-1686, also called as Rociletinib, is an oral tyrosine kinase inhibitor that irreversibly and s...

CAS 184475-35-2 Gefitinib

Gefitinib
(CAS: 184475-35-2)

Gefitinib effectively inhibits all tyrosine phosphorylation sites on EGFR in both the high and low-EGFR-expressing cell lines including NR6, NR6M and NR6W cell ...

CAS 1214265-57-2 WZ-8040

WZ-8040
(CAS: 1214265-57-2)

WZ8040 is a novel mutant-selective irreversible EGFRT790M inhibitor with potential anticancer activity. WZ8040 is about 30-fold more potent against EGFR T790M, ...

EGF816
(CAS: 1508250-71-2)

EGF816, also called as Nazartinib, a covalent mutant-selective EGFR inhibitor and potently inhibits the T790M resistance mutation while sparing wild-type EGFR. ...

CAS 1421373-66-1 AZD-9291 mesylate

AZD-9291 mesylate
(CAS: 1421373-66-1)

AZD-9291 is a third-generation EGFR inhibitor, showed promise in preclinical studies and provides hope for patients with advanced lung cancers that have become ...

CAS 1374640-70-6 CO1686

CO1686
(CAS: 1374640-70-6)

EAI045
(CAS: 1942114-09-1)

EAI045 is an allosteric, non-ATP competitive inhibitor of mutant EGFR. In vitro studies proved that EAI045 is active and selective for T790M- harboring EGFR mut...

CAS 118409-57-7 AG-18

AG-18
(CAS: 118409-57-7)

AG 18 (10 μM) inhibits EGF-induced proliferation of GH3 cells.

CAS 183320-51-6 OSI-420

OSI-420
(CAS: 183320-51-6)

OSI-420 (CP-473420) is an active metabolite of erlotinib which is an orally active EGFR tyrosin kinase inhibitor with IC50 of 2 and 20 nM for the inhibition of ...

Reference Reading


1.Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors.
Soria JC1, Cortes J, Massard C, Armand JP, De Andreis D, Ropert S, Lopez E, Catteau A, James J, Marier JF, Beliveau M, Martell RE, Baselga J. Ann Oncol. 2012 Feb;23(2):463-71. doi: 10.1093/annonc/mdr137. Epub 2011 May 16.
PURPOSE: We studied the safety, tolerability, and recommended dose of BMS-599626, an orally bioavailable inhibitor of the human epidermal growth factor receptor (HER) family of receptor tyrosine kinases.
2.AC480, formerly BMS-599626, a pan Her inhibitor, enhances radiosensitivity and radioresponse of head and neck squamous cell carcinoma cells in vitro and in vivo.
Torres MA1, Raju U, Molkentine D, Riesterer O, Milas L, Ang KK. Invest New Drugs. 2011 Aug;29(4):554-61. doi: 10.1007/s10637-010-9389-3. Epub 2010 Feb 2.
PURPOSE: The present study investigated the effect of AC480, a small molecule pan-HER tyrosine kinase inhibitor, on in vitro radiosensitivity and in vivo radioresponse of a human head and neck squamous cell carcinoma cell line.